Could two extra drugs revive immunotherapy for tough lung cancers?
Disease control
Completed
This early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Marron • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC